FULC
USDFulcrum Therapeutics Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$8.830
Haut
$9.020
Bas
$8.300
Volume
0.37M
Fondamentaux de l'Entreprise
Capitalisation Boursière
453.0M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.53M
Bourse
NGM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7
RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics with a Sector Perform and raises the price target from $5 to $7.
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16
Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics with a Overweight and raises the price target from $12.5 to $16.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.